Tools
Stock profile

BioNTech SE (BNTX)

BNTX · Latest close $83.26 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$83.26
As of Nov 18, 2026
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
1
vs previous quarter

BioNTech SE (BNTX) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $84.2M sold). Latest close $83.26 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 9, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-84.2M
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Flossbach von Storch · Dodge & Cox Funds · Baker Bros. Advisors — 3 tracked funds hold BNTX. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 26 sales ($84.2M). Insider trading

Often held alongside

AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Flossbach von Storch0.94%2,226,138TRIMMED (-39.5%) Q3 filed Oct 28
Dodge & Cox Funds0.18%3,677,591HELD Q3 filed Nov 13
Baker Bros. Advisors0.06%119,743HELD Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -9.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

126.8881.522024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding284 of 8,857 filers
Long-only filers among them281
Change vs 2026 Q1+11 net · 271 entered · 260 exited
Shares reported, all filers46,725,368
Reported value, all filers$4.3B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Net income · FY2025-1.1B EUR
Total assets · FY202522.0B EUR
Shares outstanding251,204,366
Market cap (at latest close)$20.9B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Mar 27, 2026.

Short interest

Shares short · Oct 15, 20262,272,174
Share of shares outstanding0.90%
Days to cover2.06

Shares short at recent settlements — Jul 31, 2026: 2.5M · Aug 14, 2026: 2.5M · Aug 31, 2026: 2.3M · Sep 15, 2026: 2.3M · Sep 30, 2026: 2.5M · Oct 15, 2026: 2.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Mar 27, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 56 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Mar 27, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 26 sales by 1 insider ($84.2M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Oct 9, 2026Sahin UgurChief Executive OfficerSell36,209$95.37$3.5MSEC filing
Oct 8, 2026Sahin UgurChief Executive OfficerSell27,000$92.31$2.5MSEC filing
Oct 7, 2026Sahin UgurChief Executive OfficerSell24,000$95.86$2.3MSEC filing
Oct 6, 2026Sahin UgurChief Executive OfficerSell21,000$96.81$2.0MSEC filing
Oct 5, 2026Sahin UgurChief Executive OfficerSell72,000$97.23$7.0MSEC filing
Oct 2, 2026Sahin UgurChief Executive OfficerSell17,000$96.72$1.6MSEC filing
Oct 1, 2026Sahin UgurChief Executive OfficerSell17,000$97.46$1.7MSEC filing
Sep 30, 2026Sahin UgurChief Executive OfficerSell32,000$98.12$3.1MSEC filing
Sep 29, 2026Sahin UgurChief Executive OfficerSell34,000$98.26$3.3MSEC filing
Sep 28, 2026Sahin UgurChief Executive OfficerSell34,000$98.47$3.3MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 3, 2026Medine GmbHOfficer, 10% Stockholder858,209$89.1MSep 3, 2026SEC filing
May 12, 2026Medine GmbHOfficer, 10% Stockholder858,209$80.4MMay 13, 2026SEC filing
Mar 11, 2026Poetting SierkOfficer150,000$12.6MMar 11, 2026SEC filing
Feb 12, 2026Medine GmbHOfficer, 10% Stockholder858,209$93.9MFeb 12, 2026SEC filing
Nov 28, 2025Tureci OzlemOfficer123,331$12.7MNov 28, 2025SEC filing
Nov 13, 2025Medine GmbHOfficer, 10% Stockholder1,114,130$124.4MNov 13, 2025SEC filing
Nov 5, 2025Jeggle Helmut WolfgangDirector150,000$15.5MNov 5, 2025SEC filing
Sep 5, 2025ATHOS KG10% Stockholder500,000$56.2MSep 5, 2025SEC filing
Aug 15, 2025Medine GmbHOfficer, 10% Stockholder1,774,837$200.0MAug 15, 2025SEC filing
Aug 15, 2025Tureci OzlemOfficer185,001$20.8MAug 15, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 15, 2026SC 13G/A———SEC filing
May 14, 2026ATHOS KGSC 13G/A101,702,37840.2%Mar 31, 2026SEC filing
May 13, 2025Medine GmbHSC 13G/A40,127,69716.7%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

This stock does not currently pass any tracked screen.

Signal record

· Politician BEST — appeared in 2 of the last 20 quarterly lists; latest 2024 Q2, ranked #43 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Share count tripled (3x)250.0%-10.1%+0.2%-10.3%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold BNTX — ranked by lift, the co-holding pattern described in Methodology: AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN) · BIO-TECHNE Corp (TECH) · Vaxcyte, Inc. (PCVX).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

No Form 8-K filings for this ticker in the index (Jan 2023 – present).

Related

AMGEN INC (AMGN) · Track Record: how the signals scored · Practice timing on BNTX

One email a week: the week’s new filings and research. Subscribe free

← BNTC  ·  BNY →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.